Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Moderna Inc. (Nasdaq: MRNA)

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators. Headquartered in Cambridge, Mass., with a European headquarters in Basel, Switzerland, Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. *

 

Period Start 2018-08-01 renamed
  Group Moderna (Group)
  Predecessor Moderna Therapeutics Inc.
Products Industry mRNA-based drug
  Industry 2 mRNA technology
Person Person Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly)
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 200 Technology Square
  City 02139 Cambridge, MA
  Tel +1-617-714-6500
    Address record changed: 2020-12-02
     
Basic data Employees E: 501 to 1,000 (2020-02-12)
  Currency USD
  Annual sales 60,209,000 (revenue, total, consolidated (2019) 2019-12-31)
  Profit -514,021,000 (2019-12-31)
  Cash 1,103,000,000 (2019-12-31)
     
    * Document for �About Section�: Moderna, Inc.. (9/16/20). "Press Release: Moderna Announces First Commercial Organization Outside North America in Switzerland". Cambridge, MA.
     
   
Record changed: 2021-09-13

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Moderna (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px




» top